Formulation Development
Oral Delivery of Hydrophilic Macromolecules: Lipid-Based Nanocarriers as Key to Success
This LIVE event has already taken place CLICK HERE to access the recorded version of this event and receive a copy of the presentation. Join…
SCYNEXIS Announces Licensing Agreement & Strategic Partnership With Hansoh Pharma
SCYNEXIS, Inc. recently announced it has entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group Company Limited…..
Biomunex Pharmaceuticals Signs Strategic License & Co-development Agreement With Onward Therapeutics
Biomunex Pharmaceuticals and Onward Therapeutics SA recently announced the signing of a strategic exclusive worldwide license and co-development agreement for a proprietary….
Altimmune Announces FDA Clearance of Single-Dose, Needle-Free, Intranasal COVID-19 Vaccine Candidate
Altimmune, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID….
Lonza Expands Solid Form Screening Services for Accelerated Development of Small Molecule Drugs
Lonza recently announced an expansion of its solid form selection services based at its Bend, OR, site. The increased service capabilities and dedicated team complement…
Synairgen Announces Dosing Has Commenced With Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients
Synairgen plc recently announced that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase 2/3 trial evaluating patients with…
Progenity Initiates Safety & Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
Progenity, Inc. recently announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device. The…
Enlivex Announces Issuance of New US Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis & GvHD Using Allocetra Immunotherapy
Enlivex Therapeutics Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,927,343 covering Allocetra, the company’s immunotherapy product candidate. The…
Artelo Biosciences Announces Positive Pre-Clinical Data Associated With Proprietary CBD Cocrystal
Artelo Biosciences, Inc. recently announced Saoirse O’Sullivan, PhD, Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of…
Maravai LifeSciences Expands Its Intellectual Property Portfolio
Maravai LifeSciences, Inc. recently announced the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary…..
Quotient Sciences Acquires UK-Based Contract Development & Manufacturing Organization
Quotient Sciences, the drug development and manufacturing accelerator, recently announced it has acquired Arcinova, the UK-based multiservice contract development and….
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
Celon Pharma S.A. recently announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in….
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDAr as First-line Treatment for HPV+ Recurrent/Metastatic Head & Neck Cancer
Cue Biopharma, Inc. recently announced the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck's anti-PD-1…
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines & Therapeutics
OliX Pharmaceuticals, Inc. recently announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and…
Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain & Sedation Drug Candidate
Melt Pharmaceuticals, Inc. recently announced results from its MELT Phase 1 study, a comparative bioavailability study with the objective of characterizing the pharmacokinetic parameters of…
uniQure Announces Positive Recommendation From Data Safety Monitoring Board of Phase 1/2 Clinical Trial
uniQure N.V. recently announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s…
Hyloris & Purna Female Healthcare Announce Development Partnership
Hyloris Pharmaceuticals SA and Purna Female Healthcare recently announced they have entered into a partnership to develop and commercialize an innovative combination therapy for the…
Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate With Multi-Modal Mechanism of Action in Parkinson’s Disease
Emerald Health Pharmaceuticals Inc. recently published a scientific article in the peer-reviewed journal, Molecular and Cellular Neuroscience, highlighting data supporting the potential of EHP’s drug…
Trizell Signs Development & Manufacturing Agreement With Catalent for Macrophage-Based Advanced Cell Therapy
Catalent recently announced it has signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of…
ProPerma™ Oral Formulation Technology
ProPerma™ uniquely improves both permeability and bioavailability of BCS III and BCS IV compounds by deploying an innovative and bespoke combination of GRAS and novel enhancing excipients…
